Nature Reviews Rheumatology
(ISSN: 1759-4790)
Formerly Nature Clinical Practice Rheumatology
Show only:
Full-text on Medscape | Journal CME
2009 - 5 (10)
- Rejuvenating the immune system in rheumatoid arthritis.
- Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis.
- CD19: a promising B cell target for rheumatoid arthritis.
- Dendritic cells as targets for therapy in rheumatoid arthritis.
- Regulatory T cells as therapeutic targets in rheumatoid arthritis.
- G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis.
- IL-17 as a future therapeutic target for rheumatoid arthritis.
- Promising bone-related therapeutic targets for rheumatoid arthritis.
- Treatment of rheumatoid arthritis: state of the art 2009.
- Inflammation: canakinumab for the cryopyrin-associated periodic syndromes.
- Therapy: rituximab and PML risk-informed decisions needed!
- Epidemiology: knee injuries in female athletes.
- Are new agents needed to treat RA?
